| Name | peroxisome proliferator activated receptor alpha |
|---|---|
| Synonyms | NR1C1; PPAR; PPAR alpha; PPARA; PPARalpha; Peroxisome proliferator activated receptor; Peroxisome proliferator activated receptor alpha; hPPAR… |
| Name | TCA |
|---|---|
| CAS | 2,2,2-trichloroacetic acid |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 15363585 | Laughter AR, Dunn CS, Swanson CL, Howroyd P, Cattley RC, Corton JC: Role of the peroxisome proliferator-activated receptor alpha (PPARalpha) in responses to trichloroethylene and metabolites, trichloroacetate and dichloroacetate in mouse liver. Toxicology. 2004 Oct 15;203(1-3):83-98. |
9(0,0,0,9) | Details |
| 15067378 | Shimamoto Y, Hirota K, Fukamizu A: Effect of peroxisome proliferator-activated receptor alpha on human angiotensinogen promoter. Int J Mol Med. 2004 May;13(5):729-33. |
5(0,0,0,5) | Details |
| 18821149 | Corton JC: Evaluation of the role of peroxisome proliferator-activated receptor alpha (PPARalpha) in mouse liver tumor induction by trichloroethylene and metabolites. Crit Rev Toxicol. 2008;38(10):857-75. |
5(0,0,0,5) | Details |
| 18469201 | Satapati S, He T, Inagaki T, Potthoff M, Merritt ME, Esser V, Mangelsdorf DJ, Kliewer SA, Browning JD, Burgess SC: Partial resistance to peroxisome proliferator-activated receptor-alpha agonists in ZDF rats is associated with defective hepatic mitochondrial metabolism. Diabetes. 2008 Aug;57(8):2012-21. Epub 2008 May 9. |
4(0,0,0,4) | Details |
| 15033542 | Walgren JL, Jollow DJ, McMillan JM: Induction of peroxisome proliferation in cultured hepatocytes by a series of halogenated acetates. Toxicology. 2004 May 3;197(3):189-97. Induction of peroxisome proliferation via activation of the peroxisome proliferator-activated receptor alpha (PPARalpha) has been proposed as a mechanism for their hepatocarcinogenic action. |
3(0,0,0,3) | Details |
| 19968882 | Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome proliferator-activated receptor delta from Peroxisome proliferator-activated receptor gamma in the ob/ob mouse. Genome Med. 2009 Dec 7;1(12):115. BACKGROUND: The peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors and members of the nuclear receptor superfamily. |
2(0,0,0,2) | Details |
| 19542201 | Bugger H, Chen D, Riehle C, Soto J, Theobald HA, Hu XX, Ganesan B, Weimer BC, Abel ED: Tissue-specific remodeling of the mitochondrial proteome in type 1 diabetic akita mice. Diabetes. 2009 Sep;58(9):1986-97. Epub 2009 Jun 19. In contrast, state 3 respirations, ATP synthesis, and mitochondrial cristae density were decreased in cardiac mitochondria and were accompanied by coordinate repression of OXPHOS and peroxisome proliferator-activated receptor (PPAR)-gamma coactivator (PGC)-1alpha transcripts. |
1(0,0,0,1) | Details |
| 18059612 | Muoio DM, Koves TR: Skeletal muscle adaptation to fatty acid depends on coordinated actions of the PPARs and PGC1 alpha: implications for metabolic disease. Appl Physiol Nutr Metab. 2007 Oct;32(5):874-83. Emerging evidence suggests that normal physiological adaptations to a heavy lipid load depend on the coordinated actions of broad transcriptional regulators such as the peroxisome proliferator activated receptors (PPARs) and PPAR gamma coactivator 1 alpha (PGC1 alpha). |
1(0,0,0,1) | Details |
| 19458390 | Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, Milburn MV, Ryals JA, Beebe KD, Guo L: Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol Pathol. 2009;37(4):521-35. Peroxisome proliferator-activated receptor-alpha (PPARalpha) agonists such as fenofibrate are used to treat dyslipidemia. |
1(0,0,0,1) | Details |
| 18565563 | Ramdhan DH, Kamijima M, Yamada N, Ito Y, Yanagiba Y, Nakamura D, Okamura A, Ichihara G, Aoyama T, Gonzalez FJ, Nakajima T: Molecular mechanism of trichloroethylene-induced hepatotoxicity mediated by CYP2E1. Toxicol Appl Pharmacol. 2008 Sep 15;231(3):300-7. Epub 2008 May 2. TRI significantly upregulated PPARalpha, which might function to inhibit NFkappaB p50 and p65 signalling. |
1(0,0,0,1) | Details |